The histological diagnosis of low-grade astrocytomas and oligodendrogliomas (WHO grade II) is often challenging, particularly in cases that show both astrocytic and oligodendroglial differentiation. We carried out gene expression profiling on 17 oligodendrogliomas (93% with LOH 1p and/or 19q) and 15 low-grade astrocytomas (71% with a TP53 mutation), using a cDNA array containing 1176 cancer-related genes. In oligodendrogliomas, 40 genes showed on average higher expression (at least a two-fold increase) than in astrocytomas, including DES, TDGF1, TGF-b, GABA-BR1A, Histone H4, CDKN1A, PCDH43, Rho7 and Jun-D, while 39 genes were expressed at lower levels (at least a two-fold decrease), including JNK2, ITGB4, JNK3A2, RhoC, IFI-56K, AAD14 and EGFR. Immunohistochemistry revealed nuclear staining of Jun-D in oligodendrogliomas, in contrast to the immunoreactivity of cytoplasm and cell processes in low-grade astrocytomas. Partial leastsquares analysis of the 79 genes at least two-fold differentially expressed between oligodendrogliomas and low-grade astrocytomas demonstrated perfect separation of oligodendrogliomas from low-grade astrocytomas and normal cerebral white matter. Clustering analysis based on the entire gene set divided the 17 subjects with oligodendrogliomas into two subgroups with significantly different survival (log-rank test, P ¼ 0.0305; survival to 5-years, 80 vs 0%, P ¼ 0.048). These results demonstrate that oligodendrogliomas and low-grade astrocytomas differ in their gene expression profiles, and that there are subgroups of oligodendroglioma with distinct expression profiles related to clinical outcome.
Introduction
Gliomas are the most common primary brain tumors and show wide diversity with respect to location, morphology, genetic status and response to therapy. Low-grade diffuse astrocytomas (WHO Grade II) are well-differentiated tumors typically affecting young adults and are located preferentially in the cerebral hemispheres. They grow slowly but have an inherent tendency for malignant progression to anaplastic astrocytoma (WHO grade III) and eventually, glioblastoma (WHO grade IV) . Oligodendrogliomas (WHO grade II) are similarly well-differentiated, slowly growing tumors of adults, typically located in the cerebral hemispheres, and may progress to anaplastic oligodendroglioma (WHO grade III) (Reifenberger et al., 2000) .
The histological diagnosis of oligodendrogliomas and low-grade astrocytomas can be difficult, leading to marked interobserver variability, particularly in cases that lack the typical patterns of astrocytic and oligodendroglial differentiation. This is partly due to the lack of specific and reliable markers for neoplastic oligodendrocytes. Olig 1 and Olig 2 are oligodendroglial lineage genes and have been shown by in situ hybridization to be strongly expressed in oligodendrogliomas and absent or weakly expressed in astrocytomas (Lu et al., 2001; Marie et al., 2001) . However, recent studies using immunohistochemistry on paraffin sections revealed cross-reaction of Olig 1 and Olig 2 with antigens present in both oligodendrogliomas and astrocytomas (Azzarelli et al., 2003; Ligon et al., 2003) , and Oligo 2 seems not to be a specific histologic marker for oligodendroglial tumors (Ohnishi et al., 2003) .
Another approach to distinguish these gliomas is genetic profiling. Low-grade astrocytomas contain a high frequency of TP53 mutations (465%) , while the genetic hallmark of oligodendrogliomas is LOH on 1p and/or 19q in 480% of typical cases (Reifenberger et al., 1994 (Reifenberger et al., , 2000 Perry 2001 Huang et al., 2000; Sallinen et al., 2000; Markert et al., 2001; Rickman et al., 2001; Gutmann et al., 2002; Tanwar et al., 2002) and oligodendrogliomas (Fuller et al., 1999; Watson et al., 2001; Mukasa et al., 2002) with different histological grades. However, a direct comparison between low-grade oligodendrogliomas and astrocytomas has not previously been carried out. In the present study, we performed gene expression profiling for 17 oligodendrogliomas (WHO grade II) and 15 low-grade diffuse astrocytomas (WHO grade II) using a cDNA array with 1176 cancer-related genes. Hierarchical clustering and partial least squares (PLS) analyses were employed to test whether astrocytomas and oligodendrogliomas could be separated according to their gene expression patterns, and whether subgroups within a histologic type could be identified.
Results

Genetic alterations
TP53 mutations were detected in 10 of 14 (71%) lowgrade astrocytomas and in one of 15 (7%) oligodendrogliomas analysed.
Among 15 oligodendrogliomas, LOH 1p was detected in one case, 19q in three cases and 1p and 19q in 10 cases. Overall, LOH 1p and/or 19q occurred in 14 of 15 (93%) oligodendrogliomas analysed in this study. In addition, LOH 1p was detected in 1/14 (7%) cases of low-grade astrocytoma.
Gene expression patterns in oligodendrogliomas vs astrocytomas and normal brain tissue Expression profiles of 32 tumor biopsies and four normal brain tissue samples were obtained by cDNA probe hybridization to Atlas Human Cancer 1.2 Arrays (Figure 1 ). To validate the cDNA array data, we performed semiquantitative RT-PCR for six genes: CDKN1A, Rho 7, PCDH43, histone H4, calmodulin and AAD14. The results obtained by RT-PCR were consistent with their up-or downregulations observed on cDNA arrays (Figure 1 ).
Averaged arrays for oligodendrogliomas, low-grade diffuse astrocytomas and normal control brain tissue were generated by pooling data from 17 oligodendrogliomas, 15 low-grade diffuse astrocytomas and four normal brain tissue samples. Comparison of the averaged array of oligodendrogliomas to that of lowgrade astrocytomas identified 79 genes with a ratio of Figure 1 Representative cDNA array autoradiographs (upper panel) and data validation by semiquantitative RT-PCR (lower panel). Spots 1-6 in the autoradiographs correspond to PCDH43, Rho 7, CDKN1A, histone H4, calmodulin and AAD14, respectively. The mean ratio of band intensities (Oligo/LGA) on RT-PCR was 2.16 for PCDH43, 2.64 for Rho 7, 3.53 for CDKN1A, 5.94 for histone H4, 0.34 for calmodulin and 0.49 for AAD14, respectively, consistent with their up-or downregulations observed on cDNA arrays (Table 1) . The mean ratio of autoradiograph intensities (Oligo/LGA) on cDNA array is 0.59 for calmodulin. NBT, normal brain tissue (cerebral white matter); Oligo, oligodendroglioma; LGA, low-grade astrocytoma; ÀRT, without reverse-transcriptase in cDNA synthesis; H 2 O, negative control with H 2 O Gene expression profiling in oligodendrogliomas H Huang et al X2 or p0.5 and an absolute intensity difference of X2500. The two-fold cutoff threshold was chosen a posteriori to result in a manageably large subset of genes for subsequent analysis, which would be likely to contain any information concerning the separation of samples according to variation in gene expression. The averaged oligodendroglioma array was also compared with the averaged normal tissue array to determine mean fold change between oligodendroglioma and normal brain tissue (Table 1) .
Subtype analysis using hierarchical clustering and PLS models
Included in these analyses were all 17 oligodendrogliomas, 15 low-grade astrocytomas and four normal brain tissue samples. A preliminary hierarchical clustering analysis based on the entire set of genes present on the array separated the samples into several groups (nodes) without clear distinction between low-grade astrocytomas and oligodendrogliomas, although the four normal brain samples were separated from the tumors and formed a unique node (data not shown). We then carried out cluster analysis based on the 79 differentially expressed genes between low-grade astrocytomas and oligodendrogliomas (X2-fold difference on average). The four normal brain tissue samples were clustered in the same node and 14 of 15 (93%) low-grade astrocytomas were separated from oligodendrogliomas and normal brain tissue samples ( Figure 2 ). Although hierarchical clustering largely identified the tissue classes based on the expression data, the lack of visualizable expression patterns in Figure 2 suggests that expression differences among the tissues may be due to the interaction of more than one biological process. Thus, we chose to employ PLS to seek a lowdimensional projection of the 79-dimensional gene space that would be most informative for classification of the tissues. The same data set from the 79 genes used for hierarchical clustering was employed for PLS. Prior to PLS model estimation, 10 completed data sets were obtained using a Gaussian model and data augmentation employing an equal number of independent chains. A PLS model was generated for each completed data set and informally compared. As these gave very similar results, only the results of the PLS analysis on our first completed data set is presented in Figure 3 . Clear and perfect separation of the tissue classes was found to occur in a plane composed of the first two PLS components.
Jun-D expression
Array analysis revealed that mRNA levels of Jun-D in oligodendrogliomas were upregulated three-fold compared to low-grade astrocytomas and 1.8-fold, compared to normal brain tissue (Table 1) . Immunohistochemically, neoplastic oligodendrocytes typically showed nuclear staining (Figure 4b ), although the fraction of positive cells and the staining intensity varied significantly (Table 2 ). In contrast, neoplastic astrocytes showed Jun-D expression typically in the cytoplasm and cell processes ( Figure 4d ) and rarely nuclear immunoreactivity, except for cells with round nuclei that appeared to be trapped nonneoplastic oligodendrocytes. Nuclear staining was also observed in oligodendrocytes of normal brain samples.
Presence of subgroups among oligodendrogliomas
Clustering analysis of 17 oligodendroglioma and four normal brain tissue samples based on the entire set of genes separated the four normal brain tissues from the oligodendrogliomas; eight oligodendrogliomas were clustered closely to normal brain tissues in one subgroup and nine oligodendrogliomas in another subgroup ( Figure 5 ). We compared the clinical and genetic data and patient survival between tumors in these two subgroups (Oligo A and Oligo B). Oligo A showed a significantly higher 5 year survival rate (80 vs 0%, P ¼ 0.048, Fisher's exact test) and a longer survival ( Figure 6 ) than Oligo B, while age, sex, TP53 mutations and LOH 1p/19q status have no significant difference between the two subgroups (Table 3) .
Clustering analysis with 15 low-grade astrocytomas and four normal brain samples based on the entire set of genes separated the four normal samples from low-grade astrocytomas, but did not show any grouping between fibrillary and gemistocytic astrocytomas or between 
Gene expression during oligodendroglioma progression
Of the 17 oligodendrogliomas included in this study, two tumors (Oligo 08 and Oligo 10) were from the same patient. The second biopsy (Oligo 08) was taken 5 years after the first biopsy (Oligo 10). This patient died 4.5 years after the second biopsy. Expressions of a subset of genes including EGFR, AAD14, SPARC, c-myc and GDNPF were increased, whereas those of IgG, IgG3, CASP10 and HLA class II histocompatibility antigen were decreased in the second biopsy comparing to the first biopsy. Hierarchical clustering analysis placed the first biopsy in the Oligo A subgroup and the second in the Oligo B subgroup ( Figure 5 ).
Discussion
Gene expression-based classification of tumors has been used in a number of studies for various types of brain tumors and has been shown to be a useful tool for tumor classification and identification of tumor subtypes with distinct clinical outcome. Patterns of gene expression have distinguished grade I and grade II astrocytomas from glioblastomas (Rickman et al., 2001) , sporadic pilocytic astrocytomas from NF-1 associated pilocytic astrocytomas (Gutmann et al., 2002) , oligodendrogliomas from anaplastic oligodendrogliomas (Watson et al., 2001) , and oligodendrogliomas with 1p loss from those without 1p loss (Mukasa et al., 2002) . Nutt et al. (2003) have shown that gene expression-based classification of high-grade gliomas (anaplastic oligodendrogliomas and glioblastomas) correlates better with survival than histological classification.
In the present study, we compared gene expression profiles of oligodendrogliomas (WHO grade II) and low-grade diffuse astrocytomas (WHO grade II). Only histologically typical cases were included in this study, and this is confirmed by the high frequency of TP53 mutations in low-grade astrocytomas (71%) and LOH 1p and/or 19q in oligodendrogliomas (93%). Clustering analysis based on the entire gene set on the array did not distinguish oligodendrogliomas from low-grade astro- cytomas. However, analysis using 79 genes differentially expressed (X2 fold difference on average) between the two tumor types clearly separated the low-grade astrocytomas from oligodendrogliomas ( Figure 3 ). These results demonstrate that oligodendrogliomas and low-grade astrocytomas differ in their gene expression profiles and that the 79 differentially expressed genes identified in the present study may serve as a basis for further studies to establish a customized array for the purpose of diagnosis of these subtypes of low-grade gliomas. In this context, we note that a major benefit of the PLS model is that it can be easily employed to classify new samples. To the degree that the two identified components may reflect the effect of two interacting biological processes, the PLS model can also be used to identify genes with similar relationships to each other, to the components, and thereby to the underlying biological processes. Clustering analysis using the entire set of genes divided 17 oligodendrogliomas into two subgroups ( Figure 5 ). The gene expression pattern of one subgroup (Oligo A) showed at least six nodes composed of 80 genes (data not shown) that had expression levels more similar to those in normal tissues. Among these, PDGFA, BIN1, AFGF, TDGF1 and IGFBP2 showed higher expression in normal tissue and Oligo A than in Figure 4 Differential expression of Jun-D in oligodendrogliomas (a) and low-grade astrocytomas (c). Jun-D immunohistochemistry shows nuclear staining of oligodendroglioma cells (b), whereas in low-grade astrocytoma, immunoreactivity is largely restricted to the cytoplasm and cell processes (d) Figure 3 Plot of three types of tissues (oligodendroglioma, lowgrade astrocytoma and normal brain) projected onto the plane formed by the first two components identified by a partial leastsquares (PLS) regression models. The same subset of data from 79 genes as in Figure 2 was used in this analysis. The three tissue types are clearly separated in this two-dimensional plane. , normal brain tissue (N1-N4); ', oligodendroglioma (O1-O17); m, low-grade astrocytoma (L1-L15) Figure 6 ). LOH on chromosome 1p/19q has been reported to be a strong predictor of longer survival of oligodendroglioma WHO grade II (Smith et al., 2000) patients and of favorable response to chemotherapy of patients with anaplastic oligodendroglioma (Cairncross et al., 1998; Ino et al., 2001 ). There was no significant difference regarding LOH 1p/19q status between the two subgroups of oligodendrogliomas identified by clustering analysis (Oligo A, 86% vs Oligo B, 100%, Table 3 ). Since these subgroups also appeared after exclusion of tumors without LOH 1p/19q, this suggests the presence of oligodendroglioma subgroups with similar LOH status but different prognosis. We were able to compare two oligodendrogliomas from the same patient, the first at initial diagnosis, the second after a 5-year interval. By cluster analysis, the first biopsy (Oligo 10) fell into Oligo A and the second (Oligo 08) into Oligo B (Figure 5 ). It is also notable that several genes including EGFR, c-myc, AAD14, SPARC and GDNPF showed higher expression in the second biopsy, consistent with their potential roles in tumor growth and progression (Huang et al., 2000) , while several immune system proteins (IgG, IgG3 and HLA class II histocompatibility antigen) and an apoptosis-related protein CASP10 were downregulated in the second biopsy in comparison to the first biopsy. This observation suggests that the differences in expression profile reflect tumor progression and that Oligo A may be the precursor of Oligo B. Direct comparison between oligodendrogliomas and low-grade astrocytomas identified a number of genes differentially expressed in these tumors. Genes up-or downregulated in oligodendrogliomas (Table 1) are involved in various molecular processes such as transcription and translation (Rho7, HPH2, Jun-D, histone H4), cell cycle control and apoptosis (CCND2, CCND1, CDKN1A, TRAP1, p68 kinase, CASP9) and cell adhesion and migration (PCDH43, Tenascin-R, ITGB4). Among the significantly upregulated genes, Rho7 is a member of the rho family of GTP-binding proteins. Rho proteins are key regulators of the actin cytoskeleton and through their interaction with multiple target proteins, they control other cellular activities such as gene transcription and adhesion (Hall, 1998) . Protocadherin-43 mediates Ca 2 þ -dependent and specific homophilic cell-cell interaction and plays an important role in cell adhesion, cell recognition and other basic cell processes (Sano et al., 1993; Obata et al., 1995) . GABA-BR1A is involved in the GABAergic neurotransmission of the mammalian central nervous system and may have physiological importance and clinical relevance in several diseases such as multiple sclerosis, epilepsy and schizophrenia (Grifa et al., 1998; Peters et al., 1998) . The roles of these genes in the development of oligodendrogliomas have not been reported yet. CDKNA1 (p21) expression has been positively correlated with TP53 expression in oligodendrogliomas and was shown in one study (Miettinen et al., 2001) to have independent prognostic significance.
In order to reliably distinguish histologically between oligodendroglial and astrocytic tumors, it is important to identify reliable gene expression markers. One potential marker identified in this study is Jun-D, which encodes a component of the transcription factor AP-1 that mediates the response to extracellular signaling (Vogt 2001; Wagner 2001) . Jun-D forms homodimers or heterodimers with other members of the Jun and/or Fos gene families. These dimers bind to the TGACTCA consensus sequence present in numerous promoters. Jun-D has been implicated in the control of cell proliferation and apoptosis in ovarian cancer cells (Gunthert et al., 2002) and in myeloblastic leukemia ML-1 cells in response to extracellular stimuli. Constitutive activation of Jun-D and NF-kB p50/p65 is essential for deregulated interleukin 6 expression in prostate cancer and has been suggested as a potential entry point for therapeutic intervention (Zerbini et al., 2003) . In the present study, nuclear expression of Jun-D was observed in the majority of oligodendrogliomas ( Figure 4 , Table 2 ), in line with the upregulation of Jun-D mRNA observed by cDNA array analysis (Table 1) . In low-grade astrocytomas, immunoreactivity was largely restricted to the cytoplasm and cell processes of neoplastic astrocytes, while nuclear Jun-D expression was only focally present in cells most probable resembling entrapped non-neoplastic normal oligodendrocytes. Similarly, microtubule-associated protein-2 (MAP2) has also been proposed to serve as a diagnostic marker for distinguishing oligodendrogliomas from astrocytomas based on its different cellular staining patterns, that is, perinuclear staining in oligodendrogliomas vs process staining in astrocytomas (Blumcke et al., 2001 ).
In conclusion, our cDNA array analysis identified a number of genes that are differentially expressed in oligodendrogliomas and low-grade diffuse astrocytomas. In addition, we present evidence that there are two groups of oligodendrogliomas with similar LOH status that differ in gene expression profile and clinical outcome.
Materials and methods
Brain tumors and control samples
Biopsy samples of oligodendrogliomas (WHO grade II) and low-grade diffuse astrocytomas (WHO grade II) were obtained Figure 6 Kaplan-Meier analysis (log-rank test) showing significantly longer survival for patients in oligodendroglioma subgroup A than those in oligodendroglioma subgroup B. This analysis was based on six cases in subgroup A and nine cases in subgroup B for which survival data were available We selected typical oligodendrogliomas with classical histopathological features, including a honeycomb pattern, and excluded borderline cases (Watanabe et al., 2001) . The mean age of 17 oligodendroglioma patients was 46.876.8 years (range, 32-58 years); 10 were males and seven were females. Clinical data were available for 15 cases, with a mean follow-up period of 4.6 years (range, 1.4-9.7 years). From one patient, we obtained a biopsy at first diagnosis and a second after a 5-year interval, with no change in grade (Oligo No. 8 and No. 10) . All samples were snap-frozen after surgical removal and stored at À801C until use.
We included only typical low-grade astrocytomas, excluding cases of equivocal astrocytic origin or focal oligodendroglial differentiation. Of 15 low-grade diffuse astrocytomas, 10 were fibrillary and five were gemistocytic astrocytomas. The mean age of patients was 35.8710.1 years (range, 23-56 years). Six patients were males (mean age, 36.779.0 years; range, 26-49 years) and nine were females (mean age, 35.2711.3 years; range, 23-56 years) . Results of cDNA expression profiles of eight of the 15 low-grade astrocytomas have been reported previously (Huang et al., 2000) .
As reference for cDNA array analysis, we used four nontumorous post-mortem (within 7 h after death) samples of white matter of the cerebrum obtained from the Institute of Neuropathology, University Hospital Zurich, Switzerland. A Universal Human Reference RNA derived from 10 human tumor cell lines (Stratagene, La Jolla, CA, USA) was used as a reference in preparing data for clustering and PLS analyses.
TP53 mutations
Exons 5-8 of the TP53 gene were screened for mutations in 14 low-grade astrocytomas and 15 oligodendrogliomas using SSCP followed by direct sequencing (Watanabe et al., 1996; Huang et al., 2000) . DNA sequencing was carried out with an ABI PRISMt 310 Genetic Analyser (Perkin-Elmer Biosystems, Foster City, CA, USA) using an ABI PRISM BigDyet Terminator Cycle Sequencing Ready Reaction Kit (PerkinElmer Biosystems, Foster City, CA, USA).
Analyses for LOH on chromosomes 1p and 19q
LOH on chromosomes 1p and 19q was assessed by quantitative microsatellite analysis (QuMA), according to a previously published protocol (Nigro et al., 2001 ) with some modifications. All microsatellite markers and a fluorescent internal probe for microsatellite CA repeats [5 0 -(6-Fam) TGT GTG TGT GTG TGT GTG TGT (BHQ1)-3 0 ] were obtained from Proligo Primers and Probest (Paris, France). D1S468, D1S214 and D1S2736 were used for assessment of LOH on chromosome region 1p36 and D19S408, D19S596 and D19S867 for LOH on chromosome region 19q13.3 (Nigro et al., 2001) . PCR reactions, consisting of 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems, Branchburg, NJ, USA), 0.4 mM each primer, 60 nM probe and 5 ng DNA in a total volume of 12.5 ml, were performed in triplicate for each sample in 96-well optical plates on an ABI 7900HT instrument (Applied Biosystems, Foster City, CA, USA), using the same conditions as previously described (Nigro et al., 2001) .
As controls, we used DNAs from formalin-fixed, paraffinembedded, normal tissues (cerebellum, spleen, stomach, duodenum, lymph node, tonsil and colon) from 10 unrelated individuals. To define copy number loss or gain, the tolerance interval (TI) was calculated based on a total of 60 measurements (10 normal control DNAs for six markers) using the formula previously described (Nigro et al., 2001) and copy numbers o1.27 were considered to be losses and those 43.14 were considered to be gains. LOH on 1p or 19q was considered to be positive only when at least two of the three markers showed losses.
cDNA array analysis
The Atlas Human Cancer 1.2. Arrays (BD Clontech, Palo Alto, CA, USA) containing cDNA fragments of 1176 cancerassociated human genes/clones were used. The methods of total RNA isolation, cDNA probe preparation, hybridization and signal quantification have been described previously (Huang et al., 2000) . For data normalization between cDNA arrays, preliminary analysis indicated that both 'global' mode and 'housekeeping gene' mode gave similar results and the 'global' mode was used in this study. For experiments with the Universal Human Reference RNA, we used 5 mg of DNase Itreated total RNA. cDNA probes derived from 17 oligodendrogliomas, 15 lowgrade astrocytomas, four normal brain tissue samples, and an Universal Human Reference RNA (Stratagene, La Jolla, CA, USA) were hybridized separately to an Atlas Human Cancer 1.2 Array (BD Clontech, Palo Alto, CA, USA).
cDNA array data preparation
Image data were collected and analysed using the AtlasImage 2.01 software (BD Clontech; Palo Alto, CA, USA) (Huang et al., 2000) . Adjusted signal intensity (i.e. after background subtraction and global normalization) of each gene on each array (including all normal and tumor samples) was compared to that of the Universal Human Reference RNA array. To reduce spuriously large change indices, genes that had an adjusted intensity below 10% of the background level were set to a value of 10% of the background intensity.
Averaged arrays for oligodendrogliomas, low-grade astrocytomas and normal control brain tissue were generated by pooling data from 17 oligodendrogliomas, 15 low-grade astrocytomas and four normal brain tissue samples. The averaged array of oligodendrogliomas was compared to that of low-grade astrocytomas to identify genes with at least two-fold under-or overexpression and an absolute intensity difference of at least 2500.
As available tools for PLS analysis do not handle missing data, a set of completed data sets were prepared using a Gaussian imputation model (Schafer 1997) . This model was seeded using the EM algorithm prior to commencement of Data Augmentation techniques using S þ MissingData (Insightful, Inc.).
Hierarchical cluster analysis of array data
Hierarchical clustering analysis was performed using the GeneCluster/TreeView software (http://rana.lbl.gov). The intensity ratio (sample/reference) obtained in data preparation was entered into the GeneCluster program, log 2 -transformed, median centered and normalized before being subjected to average or complete linkage clustering.
Analysis of array data using PLS regression models
Log 2 -transformed, standardized and complete ratio data from 79 genes selected from averaged normal brain, oligodendroglioma and low-grade astrocytoma arrays were analysed using a PLS regression model. The PLS model sought linear directions in the gene space that would informatively separate the three tissue classes. PLS models were fit using S-Plus and PLS libraries provided by the manufacturer (Durand et al., 2001 ). Such models have been used previously to analyse microarray data for the purposes of classification (Nguyen and Rocke, 2002) .
Statistical analysis of patient data and survival
Student's unpaired t-test was carried out to compare the mean age and mean survival of patients in two oligodendroglioma subgroups identified by cluster analysis. Fisher's exact test was used to compare gender, 5-year survival rate, TP53 mutation rate and LOH 1p/19p between patients in two subgroups of oligodendrogliomas. The log-rank test was carried out to assess univariate comparisons in survival rates.
Semiquantitative RT-PCR
First-strand cDNA synthesis and differential RT-PCR was performed as described previously (Huang et al., 2000) using the b-actin sequence as a reference. The primer sequences were as follows: 5 0 -GAG TTA TGT CCC CAC CGT GTT-3 0 (sense) and 5 0 -CAG TCC GCA TGT CCA GTT TAC-3 0 (antisense) for Rho 7; 5 0 -TGG TGG AGG TTG TGG ATG TGA-3 0 (sense) and 5 0 -GGG CGG TGA TGC TGA GGT T-3 0 (antisense) for PCDH43; 5 0 -AGG AGG CCC GTG AGC GAT GGA-3 0 (sense) and 5 0 -GGG TAC AAG ACA GTG ACA GGT-3 0 (antisense) for CDKN1A; 5 0 -GAA GCT TTT TCA CTA TTT GAC-3 0 (sense) and 5 0 -TAG CCA TTG CCA TCC TTA TCA-3 0 (antisense) for calmodulin; 5 0 -GGT TTG GGT AAG GGA GGT G-3 0 (sense) and 5 0 -CCG AAG CCG TAC AGA GTG C-3 0 (antisense) for histone H4; 5 0 -AGA ACC GAA GCA AGC CAA AGA-3 0 (sense) and 5 0 -GCT GCT CAT CCC CAG AGG-3 0 (antisense) for ADD14; 5 0 -CAA CCG CGA GAA GAT GAC C-3 0 (sense) and 5 0 -TCC AGG GCG ACA TAG CAC A-3 0 (antisense) for b-actin. PCR was carried out in a total volume of 10 ml containing 0.5 ml of cDNA solution, 0.5 U of Taq DNA polymerase (Sigma, St Louis, MO, USA), 1.5 mM MgCl 2 , 0.2 mM of each dNTP, 0.2 mM or 0.06 mM (for b-actin) of sense and antisense primers, 10 mM Tris-HCl, pH 8.3 and 50 mM KCl in a T3 Thermal Cycler (Biometra Gmbh, Gottingen, Germany) as follows: initial denaturation for 5 min at 941C, 29-33 cycles with denaturation at 941C for 30 s, annealing at 52-611C for 30 s, and extension at 721C for 30 s, followed by a final extension step for 5 min at 721C. After PCR, 5 ml of products were run on a 2% agarose gel, stained with ethidium bromide; the intensity of target and reference genes was quantified using the 1D Image Analysis Software (Kodak Digital Sciencet). Change of gene expression was then calculated as the ratio of the intensity of tumor to control samples after normalization using a factor derived from the relative intensity of the reference gene in the tumor and control samples (Huang et al., 2000) .
Jun-D protein expression
Immunohistochemistry of Jun-D was carried out on formalinfixed, paraffin-embedded sections of 30 cases of low-grade astrocytomas and 28 oligodendrogliomas. Of these, five lowgrade astrocytomas and eight oligodendroglioma cases were used in cDNA array analysis. Sections were deparaffinized in xylene and rehydrated in graded ethanol. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol for 30 min at room temperature. The sections were put in a cooker with hot antigen unmasking solution Vector H3300 (Vector Laboratories, Burlingame, CA, USA) and left to boil for 10 min, then cooled down for 30 min. After incubation with 5% skimmed milk for 1 h at room temperature, the sections were incubated overnight at 41C with the primary polyclonal antibody Jun-D (329), sc-74 (Santa Cruz, CA, USA). The reaction was visualized using Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) and 3,3 0 -diaminobenzidine solution (Vector Laboratories, Burlingame, CA, USA). The sections were then counterstained with hematoxylin. Sections without primary antibody served as negative controls.
